PRLD — Prelude Therapeutics Inc

Nasdaq · Health Care · Pharmaceuticals · CIK 1678660 ·
Last close
$6.47
Market Cap
$420.01M
52W High
$6.83
52W Low
$3.40
ADV30
457,854
Next earnings
2026-11-11
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 4,580,000 -14,177,000 -10,385,000 119,642,000 21,756,000 59,459,000
Dec 2025 5,640,000 -17,348,000 -16,457,000 141,315,000 35,256,000 72,678,000
Sep 2025 6,500,000 -20,418,000 -19,725,000 94,755,000 47,532,000 36,221,000
Jun 2025 0 -32,194,000 -31,231,000 114,918,000 25,752,000 39,080,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-43,756,000
Investing CF
$-228,000
Financing CF
$24,662,000
CapEx
$-120,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.22
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-693,446,000
Inventory
Receivables
ST Investments
$59,798,000
EBIT TTM
$-84,137,000
Pretax Income TTM
$-77,798,000
Interest Exp TTM
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$22,424,000
EBITDA
$-64,510,000
Free Cash Flow
$-13,844,625
Enterprise Value
$548,749,376
Total Cash
$151,756,992
Total Debt
$17,650,000
Shares Out
64,917,172
Trailing EPS
$-0.73
Book Value
$1.30
ROE
-57.7%
ROA
-27.2%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 12,140,000 -104,566,000 -99,498,000 141,315,000 72,678,000 -56,302,000
Dec 2024 7,000,000 -139,714,000 -127,173,000 175,515,000 44,056,000 -102,888,000
Dec 2023 0 -132,277,000 -121,832,000 277,665,000 40,575,000 -107,063,000
Dec 2022 0 -123,540,000 -115,438,000 220,500,000 25,063,000 -83,729,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.75

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $5.00 · spot: $6.47 · call volume: 104 · put volume: 1

Peers — same industry

TickerNameMarket CapLastDaily %
LRMR Larimar Therapeutics, Inc. $420.73M $4.05
ENTA ENANTA PHARMACEUTICALS INC $410.67M $14.10
BIOA BioAge Labs, Inc. $430.51M $9.38
FHTX Foghorn Therapeutics Inc. $407.98M $6.87
ARCT Arcturus Therapeutics Holdings Inc. $407.59M $14.34

News headlines (Yahoo Finance, 1h cache)

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
2026-07-17 16:00 · Yahoo
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)
2026-05-31 10:55 · Yahoo
Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
2026-05-16 14:22 · Yahoo
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-12 11:01 · Yahoo
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
2026-05-08 13:55 · Yahoo
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer
2026-05-01 09:24 · Yahoo
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cance
2026-04-20 10:00 · Yahoo
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
2026-04-15 11:30 · Yahoo
Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential
2026-08-12 16:07 · Yahoo
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
2026-07-31 13:55 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.